Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Public ClinicalTrials.gov record NCT02792231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Study identification
- NCT ID
- NCT02792231
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 955 participants
Conditions and interventions
Conditions
Interventions
- Ofatumumab subcutaneous injection Drug
- Teriflunomide-matching placebo capsules Drug
- Teriflunomide capsule Drug
- Matching placebo of ofatumumab subcutaneous injections Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2016 (Actual)
- Primary completion
- Jul 10, 2019 (Actual)
- Completion
- Oct 22, 2020 (Actual)
- Last update posted
- Nov 22, 2021
2016 – 2020
United States locations
- U.S. sites
- 59
- U.S. states
- 23
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35233-0271 | — |
| Novartis Investigative Site | Cullman | Alabama | 35058 | — |
| Novartis Investigative Site | Tucson | Arizona | 85704 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Basalt | Colorado | 81621 | — |
| Novartis Investigative Site | Boulder | Colorado | 80301 | — |
| Novartis Investigative Site | Centennial | Colorado | 80112 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative Site | Denver | Colorado | 80210 | — |
| Novartis Investigative Site | Fort Collins | Colorado | 80528 | — |
| Novartis Investigative Site | Fort Collins | Colorado | 907-280528 | — |
| Novartis Investigative Site | Fairfield | Connecticut | 06824 | — |
| Novartis Investigative Site | Newark | Delaware | 19713 | — |
| Novartis Investigative Site | Bradenton | Florida | 34205 | — |
| Novartis Investigative Site | Gainesville | Florida | 32611 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Ocala | Florida | 34471 | — |
| Novartis Investigative Site | Oldsmar | Florida | 34677 | — |
| Novartis Investigative Site | Ormond Beach | Florida | 32174 | — |
| Novartis Investigative Site | Palm Coast | Florida | 32164 | — |
| Novartis Investigative Site | Sarasota | Florida | 34243 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33713 | — |
| Novartis Investigative Site | Tallahassee | Florida | 32312 | — |
| Novartis Investigative Site | Tampa | Florida | 33603 | — |
| Novartis Investigative Site | Tampa | Florida | 33609 | — |
| Novartis Investigative Site | Tampa | Florida | 33612 | — |
| Novartis Investigative Site | Suwanee | Georgia | 30024 | — |
| Novartis Investigative Site | Anderson | Indiana | 46011 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | Wellesley | Massachusetts | 02481 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | Golden Valley | Minnesota | 55422 | — |
| Novartis Investigative Site | Billings | Montana | 59101 | — |
| Novartis Investigative Site | Great Falls | Montana | 59405 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-0001 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28806 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28202 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27405 | — |
| Novartis Investigative Site | Akron | Ohio | 44320 | — |
| Novartis Investigative Site | Columbus | Ohio | 43214 | — |
| Novartis Investigative Site | Columbus | Ohio | 43221 | — |
| Novartis Investigative Site | Westerville | Ohio | 43081 | — |
| Novartis Investigative Site | Portland | Oregon | 97225 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novartis Investigative Site | Willow Grove | Pennsylvania | 19090 | — |
| Novartis Investigative Site | Greer | South Carolina | 29650 | — |
| Novartis Investigative Site | Cordova | Tennessee | 38018 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37922 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37205 | — |
| Novartis Investigative Site | Greenville | Texas | 75401 | — |
| Novartis Investigative Site | Lubbock | Texas | 79410 | — |
| Novartis Investigative Site | Sherman | Texas | 75092 | — |
| Novartis Investigative Site | Orem | Utah | 84058 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84103 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Kirkland | Washington | 98034 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
| Novartis Investigative Site | Tacoma | Washington | 98405 | — |
| Novartis Investigative Site | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02792231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 22, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02792231 live on ClinicalTrials.gov.